Product Description
HHt-120, also called PTI-011-CI, is a capsule that is intended to be used to prevent venous thromboembolism after major orthopaedic surgery. (Sourced from:https://www.hcitinfo.com/y73tdr3kitqq.html)
Mechanisms of Action: Thrombin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Healthy Volunteers|Venous Thromboembolism
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HHT120 | P1 |
Withdrawn |
Healthy Volunteers |
2023-02-15 |
28% |
| CTR20221837 | P1 |
Unknown Status |
Venous Thromboembolism |
None |